{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:05:07Z","timestamp":1791068707058,"version":"4.1.0"},"reference-count":149,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC), the commonest among liver cancers, is one of the leading causes of mortality among malignancies worldwide. Several reports demonstrate autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) to confer increased risk of hepatobiliary malignancies, albeit at lower frequencies compared to other liver diseases. Several parameters have been recognized as risk factors for HCC development in AIH and PBC, including demographics such as older age and male sex, clinical features, the most decisive being cirrhosis and other co-existing factors, such as alcohol consumption. Moreover, biochemical activity and treatment response have been increasingly recognized as prognostic factors for HCC development in AIH and PBC. As available treatment modalities are effective only when HCC diagnosis is established early, surveillance has been proven essential for HCC prognosis. Considering that the risk for HCC is not uniform between and within disease groups, refinement of screening strategies according to prevailing demographic, clinical, and molecular risk factors is mandated in AILDs patients, as personalized HCC risk prediction will offer significant advantage in patients at high and\/or medium risk. Furthermore, future investigations should draw attention to whether modification of immunosuppression could benefit AIH patients after HCC diagnosis.<\/jats:p>","DOI":"10.3390\/cancers13051023","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T10:25:18Z","timestamp":1614594318000},"page":"1023","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1978-4602","authenticated-orcid":false,"given":"Eirini I.","family":"Rigopoulou","sequence":"first","affiliation":[{"name":"Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, 41110 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Dalekos","sequence":"additional","affiliation":[{"name":"Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, 41110 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/jjco\/hyaa130","article-title":"Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: Evidence from GLOBOCAN 2018","volume":"50","author":"Sharma","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1586\/17474124.2015.1028363","article-title":"The evolving epidemiology of hepatocellular carcinoma: A global perspective","volume":"9","author":"Wallace","year":"2015","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cam4.1998","article-title":"Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases\u2014meta-analytic assessment","volume":"8","author":"Tarao","year":"2019","journal-title":"Cancer Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/ijc.31280","article-title":"Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide","volume":"142","author":"Franceschi","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000508568","article-title":"The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017","volume":"9","author":"Lin","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_9","unstructured":"(2018, July 01). Trends in Liver Cancer Mortality Among Adults Aged 25 and Over in the United States, 2000\u20132016, Available online: https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db314.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children","volume":"336","author":"Chang","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jhep.2015.07.032","article-title":"Changing incidence patterns of hepatocellular carcinoma among age groups in Taiwan","volume":"63","author":"Hung","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2018.01.031","article-title":"Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2020.01.007","article-title":"Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B","volume":"72","author":"Papatheodoridis","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","article-title":"Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B","volume":"73","author":"Papatheodoridis","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.jhep.2014.07.010","article-title":"Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma","volume":"61","author":"Hoshida","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ng.2291","article-title":"Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators","volume":"44","author":"Fujimoto","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/2053","article-title":"The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice","volume":"4","author":"Moriya","year":"1998","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","article-title":"AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterol"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2012.09.007","article-title":"Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups","volume":"11","author":"Mancebo","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"ref_23","unstructured":"Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2019, March 21). Global Cancer Observatory: Cancer Tomorrow. International Agency for Research on Cancer, Lyon 2018. Available online: https:\/\/gco.iarc.fr\/tomorrow."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00005-019-00550-9","article-title":"Variant and specific forms of autoimmune cholestatic liver diseases: A short review","volume":"67","author":"Dalekos","year":"2019","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gershwin, M.E., Vierling, J.M., Tanaka, A., and Manns, M.P. (2020). Primary sclerosing cholangitis\u2014Autoimmune hepatitis overlap. Liver Immunology: Principles and Practice, Springer International Publishing. Chapter 23.","DOI":"10.1007\/978-3-030-51709-0"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4254\/wjh.v5.i10.577","article-title":"Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome","volume":"5","author":"Rigopoulou","year":"2013","journal-title":"World J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1665-2681(19)30914-7","article-title":"Autoimmune hepatitis in patients with chronic HBV and HCV infections: Patterns of clinical characteristics, disease progression and outcome","volume":"13","author":"Rigopoulou","year":"2014","journal-title":"Ann. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.02.001","article-title":"NAFLD and autoimmune hepatitis: Do not judge a book by its cover","volume":"75","author":"Dalekos","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rigopoulou, E.I., Gatselis, N., Arvaniti, P., Koukoulis, G.K., and Dalekos, G.N. (2021). Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. Eur. J. Intern. Med.","DOI":"10.1016\/j.ejim.2020.12.024"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2015). EASL Clinical Practice Guidelines: Autoimmune hepatitis. J. Hepatol., 63, 971\u20131004.","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"ref_31","first-page":"1","article-title":"Hellenic Association for the Study of the Liver (HASL) Clinical Practice Guidelines: Autoimmune Hepatitis","volume":"32","author":"Dalekos","year":"2019","journal-title":"Ann. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"EASL (2017). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol., 67, 145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejim.2017.05.006","article-title":"Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece","volume":"42","author":"Gatselis","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102328","DOI":"10.1016\/j.jaut.2019.102328","article-title":"The challenges of primary biliary cholangitis: What is new and what needs to be done","volume":"105","author":"Vergani","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis\u2014A comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ijc.31835","article-title":"Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults","volume":"144","author":"McGee","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.24743","article-title":"Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand","volume":"55","author":"Ngu","year":"2012","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10620-012-2525-5","article-title":"Hepatocellular Carcinoma and Other Malignancies in Autoimmune Hepatitis","volume":"58","author":"Czaja","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.28961","article-title":"Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States","volume":"65","author":"Cadier","year":"2017","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"EASL (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236.","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.bpg.2013.08.021","article-title":"Cost-effectiveness of liver cancer screening","volume":"27","author":"Cucchetti","year":"2013","journal-title":"Best Pr. Res. Clin. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/liv.14480","article-title":"Incidence, prevalence and mortality of autoimmune hepatitis in England 1997\u20132015. A population-based cohort study","volume":"40","author":"Otete","year":"2020","journal-title":"Liver Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","article-title":"Autoimmune hepatitis in Denmark: Incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study","volume":"60","author":"Vilstrup","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1111\/liv.14224","article-title":"Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs","volume":"39","author":"Valgeirsson","year":"2019","journal-title":"Liver Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.dld.2019.01.015","article-title":"Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland","volume":"51","author":"Puustinen","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","article-title":"Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands","volume":"49","author":"Verwer","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/apt.12470","article-title":"Review article: Autoimmune hepatitis\u2014Current management and challenges","volume":"38","author":"Zachou","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3748\/wjg.v21.i1.60","article-title":"Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics","volume":"21","author":"Gatselis","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.clinre.2018.12.002","article-title":"Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment","volume":"43","author":"Rigopoulou","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na\u00efve patients","volume":"55","author":"Zachou","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.13584","article-title":"A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis","volume":"43","author":"Zachou","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/hepr.13252","article-title":"Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis","volume":"49","author":"Zachou","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e238400","DOI":"10.1136\/bcr-2020-238400","article-title":"Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed","volume":"13","author":"Dalekos","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.cgh.2018.09.046","article-title":"Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis","volume":"17","author":"Brand","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1053\/j.gastro.2011.02.065","article-title":"Long-term Outcomes of Patients with Autoimmune Hepatitis Managed at a Nontransplant Center","volume":"140","author":"Hoeroldt","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.22432","article-title":"Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening","volume":"48","author":"Yeoman","year":"2008","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"301","author":"Stern","year":"1973","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.21.1.78","article-title":"Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis","volume":"21","author":"Kirk","year":"1980","journal-title":"Gut"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(20)30706-6","article-title":"Autoimmune hepatitis and cancer risk\u2014A Danish nationwide cohort study","volume":"73","author":"Jensen","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3748\/wjg.15.578","article-title":"Hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"15","author":"Teufel","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s10620-018-5441-5","article-title":"Older Age and Disease Duration Are Highly Associated with Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis","volume":"64","author":"Dakhoul","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2036.2006.03113.x","article-title":"Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis","volume":"24","author":"Miyake","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2006.03104.x","article-title":"Type I autoimmune hepatitis: Clinical course and outcome in an Italian multicentre study","volume":"24","author":"Floreani","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/j.1572-0241.2008.01922.x","article-title":"Predictive Factors for Hepatocellular Carcinoma in Type 1 Autoimmune Hepatitis","volume":"103","author":"Carpenter","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10620-010-1444-6","article-title":"Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series","volume":"56","author":"Wong","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"ref_72","first-page":"569","article-title":"Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1","volume":"47","author":"Ide","year":"2011","journal-title":"J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/hep.25658","article-title":"Long-term outcome of Japanese patients with type 1 autoimmune hepatitis","volume":"56","author":"Yoshizawa","year":"2012","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1478-3231.2011.02734.x","article-title":"Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study)","volume":"32","author":"Migita","year":"2011","journal-title":"Liver Int."},{"key":"ref_75","first-page":"217","article-title":"Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis\u2014A long-term follow-up study in 634 Swedish patients","volume":"50","author":"Almer","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/liv.14082","article-title":"Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country","volume":"39","author":"Choi","year":"2019","journal-title":"Liver Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2017.02.006","article-title":"Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis","volume":"15","author":"Tansel","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0016-5085(10)63729-8","article-title":"S1883 Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Primary Biliary Cirrhosis and Autoimmune Hepatitis","volume":"138","author":"Macaron","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1016\/S0168-8278(20)31412-4","article-title":"Hepatocellular carcinoma in patients with autoimmune hepatitis: Prevalence and risk factors","volume":"73","author":"Vaz","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/hep.1840080635","article-title":"Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis","volume":"8","author":"Wang","year":"1988","journal-title":"Hepatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.cgh.2018.11.028","article-title":"Association Between Black Race and Presentation and Liver-Related Outcomes of Patients with Autoimmune Hepatitis","volume":"17","author":"Gerussi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(99)80092-0","article-title":"Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during \u03b1-interferon treatment","volume":"30","author":"Dalekos","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO (2016). Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jgh3.12046","article-title":"Non-alcoholic fatty liver disease in patients with autoimmune hepatitis","volume":"2","author":"Takahashi","year":"2018","journal-title":"JGH Open"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1016\/S0618-8278(19)30779-0","article-title":"FRI-029-Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: Important player or innocent bystander?","volume":"70","author":"Zachou","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-016-4213-3","article-title":"Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease","volume":"61","author":"Wangensteen","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/hep.510300213","article-title":"Primary biliary cirrhosis once rare, now common in the United Kingdom?","volume":"30","author":"James","year":"1999","journal-title":"Hepatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Gershwin, M.E., Vierling, J.M., Tanaka, A., and Manns, M.P. (2020). Geoepidemiology of autoimmune liver diseases. Liver Immunology: Principles and Practice, Springer International Publishing. Chapter 11.","DOI":"10.1007\/978-3-030-51709-0"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/gast.2000.20197","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a US community","volume":"119","author":"Kim","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/apt.13448","article-title":"Population-based epidemiology of primary biliary cirrhosis in South Korea","volume":"43","author":"Kim","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s12072-019-09984-x","article-title":"Epidemiology and clinical course of primary biliary cholangitis in the Asia\u2013Pacific region: A systematic review and meta-analysis","volume":"13","author":"Zeng","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29717","article-title":"Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history","volume":"67","author":"Perez","year":"2018","journal-title":"Hepatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent Long-Term Survival in Patients with Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid","volume":"130","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1478-3231.2010.02366.x","article-title":"A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre","volume":"31","author":"Floreani","year":"2010","journal-title":"Liver Int."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/hep.25788","article-title":"Primary biliary cirrhosis and cancer risk: A systematic review and meta-analysis","volume":"56","author":"Liang","year":"2012","journal-title":"Hepatology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/hep.26176","article-title":"Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: National data from Japan","volume":"57","author":"Harada","year":"2013","journal-title":"Hepatology"},{"key":"ref_102","first-page":"266","article-title":"Increased cancer risk in a large population-based cohort of patients with primary biliary cirrhosis: Follow-up for up to 36 years","volume":"8","author":"Boonstra","year":"2014","journal-title":"Hepatol. Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: A multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Natarajan, Y., Tansel, A., Patel, P., Emologu, K., Shukla, R., Qureshi, Z., El-Serag, H.B., Thrift, A.P., and Kanwal, F. (2020). Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig. Dis. Sci., 1\u201313.","DOI":"10.1007\/s10620-020-06498-7"},{"key":"ref_105","first-page":"1160","article-title":"Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Similar Incidence to That in Hepatitis C Virus\u2013Related Cirrhosis","volume":"96","author":"Caballeria","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/MEG.0b013e3282f163ed","article-title":"Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis","volume":"20","author":"Deutsch","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12016-015-8483-x","article-title":"Incidence and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis","volume":"48","author":"Rong","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1053\/jhep.2002.33157","article-title":"Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis","volume":"35","author":"Shibuya","year":"2002","journal-title":"Hepatology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cgh.2006.09.031","article-title":"Clinical Predictors for Hepatocellular Carcinoma in Patients with Primary Biliary Cirrhosis","volume":"5","author":"Suzuki","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/hep.23095","article-title":"Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: Comparative analysis from two centers","volume":"50","author":"Cavazza","year":"2009","journal-title":"Hepatology"},{"key":"ref_111","first-page":"1495","article-title":"Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid","volume":"22","author":"Kuiper","year":"2010","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.3748\/wjg.v21.i12.3554","article-title":"Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: Incidence and risk factors","volume":"21","author":"Zhang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.1140485","article-title":"Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production","volume":"317","author":"Naugler","year":"2007","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000315247","article-title":"Gender Disparity of Hepatocellular Carcinoma: The Roles of Sex Hormones","volume":"78","author":"Yeh","year":"2010","journal-title":"Oncology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/00365521.2019.1683226","article-title":"Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis","volume":"54","author":"Abdulkarim","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","author":"Dyson","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase","volume":"115","author":"Perez","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cgh.2019.08.013","article-title":"Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis","volume":"18","author":"Gatselis","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1056\/NEJMra1506330","article-title":"Primary Sclerosing Cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2016.06.021","article-title":"Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease","volume":"151","author":"Lunder","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate with Course of Primary Sclerosing Cholangitis","volume":"152","author":"Trivedi","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.gastro.2003.07.011","article-title":"Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community","volume":"125","author":"Bambha","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis","volume":"36","author":"Bergquist","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ajg.2016.55","article-title":"Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD","volume":"111","author":"Gulamhusein","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","article-title":"High lifetime risk of cancer in primary sclerosing cholangitis","volume":"50","author":"Claessen","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.cgh.2014.02.008","article-title":"Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis","volume":"12","author":"Zenouzi","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People with Inflammatory Bowel Diseases, Based on Sex, Race, and Age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.29730","article-title":"Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis","volume":"67","author":"Ali","year":"2018","journal-title":"Hepatology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia\u2013Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2008.08.005","article-title":"Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients with Cirrhosis","volume":"6","author":"Andersson","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Singal, A.G., Pillai, A., and Tiro, J. (2014). Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001624"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: New trends","volume":"72","author":"Singal","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1038\/ctg.2017.26","article-title":"Cost-Effectiveness of Risk Score\u2013Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis","volume":"8","author":"Goossens","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.gastro.2019.02.049","article-title":"Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction","volume":"157","author":"Kanwal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2019.11.006","article-title":"Milestones in the pathogenesis and management of primary liver cancer","volume":"72","author":"Nault","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: A meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.1840100110","article-title":"Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis","volume":"10","author":"Wang","year":"1989","journal-title":"Hepatology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1582-4934.2005.tb00337.x","article-title":"The activation of Akt\/PKB signaling pathway and cell survival","volume":"9","author":"Song","year":"2005","journal-title":"J. Cell. Mol. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"11369","DOI":"10.1074\/jbc.M109.028142","article-title":"Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: Implications in skin carcinogenesis","volume":"285","author":"Han","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/tri.12372","article-title":"Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: A systematic review","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Transpl. Int."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.3748\/wjg.v25.i35.5356","article-title":"De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature","volume":"25","author":"Manzia","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1478-3231.2009.02117.x","article-title":"Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma","volume":"30","author":"Hui","year":"2010","journal-title":"Liver Int."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"685","DOI":"10.12659\/AOT.889299","article-title":"Mycophenolate mofetil in liver transplantation: A review","volume":"18","author":"Kaltenborn","year":"2013","journal-title":"Ann. Transplant."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/TP.0000000000002647","article-title":"Suppression of Hepatocellular Carcinoma by Mycophenolic Acid in Experimental Models and in Patients","volume":"103","author":"Chen","year":"2019","journal-title":"Transplantation"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/5\/1023\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:30:58Z","timestamp":1760160658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/5\/1023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":149,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["cancers13051023"],"URL":"https:\/\/doi.org\/10.3390\/cancers13051023","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}